Kura rises on $30 mln milestone payment after first patient dosed in late-stage trial
24/10/2025 15:28
Updates ** Shares of drugmaker Kura Oncology KURA.O rise 4% to $9.46 in early trading ** Company gets $30 mln milestone payment after dosing first patient in a late-stage trial for acute myeloid leukemia, a fast-growing blood cancer ** The trial tests oral experimental drug ziftomenib-plus-chemo in newly diagnosed AML patients with NPM1 or KMT2A mutations - Kura ** Adds the mutations are genetic changes found in AML; NPM1 is linked to better initial chemo response, while KMT2A is tied to aggressive disease and higher relapse risk ** Trial launch announced last month; ziftomenib is a once-daily oral treatment - Kura ** The disease affects about 22,000 people in the U.S. every year, according to the American Cancer Society ** Including session's move, stock up ~7% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))